|
시장보고서
상품코드
2077326
항경련제 시장 : 세대별, 투여 경로별, 유통 채널별, 지역별Antiepileptic Drugs Market, By Generation, By Route of Administration, By Distribution Channel, By Geography |
||||||
항경련제 시장은 2026년에 77억 4,000만 달러 규모가 될 것으로 추정되며, 2033년까지 98억 5,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 3.5%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 77억 4,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간의 CAGR: | 3.50% | 2033년 시장 규모 예측: | 98억 5,000만 달러 |
간질은 뇌에 영향을 미쳐 빈번한 발작을 일으키는 만성 질환입니다. 발작이란, 뇌 내의 전기적 활동이 갑작스럽게 증가하여 일시적으로 뇌 기능에 영향을 미치는 현상입니다. 간질은 어떤 연령대에서든 발병할 가능성이 있지만, 보통 소아기나 60세 이상에서 발병합니다. 뇌 활동을 확인하기 위해 몇 가지 검사가 실시됩니다. 간질 환자의 경우, 뇌 내의 비정상적인 전기적 활동을 확인하기 위해 뇌파 검사(EEG)가 실시됩니다. 또한 뇌 스캔은 비정상적인 증식(뇌종양), 뇌 손상, 뇌 내 흉터 등, 간질로 인해 발생할 수도 있는 뇌 내의 문제를 발견하기 위해서도 사용됩니다. 간질 환자의 뇌 스캔에는 자기공명영상(MRI) 검사도 사용됩니다. 이는 자기장과 전파를 이용하여 뇌 영상을 생성하는 것입니다. 간질 치료에는 항경련제도 사용되는데, 이들은 3가지 세대로 분류됩니다.
시장 역학
신제품 출시 건수의 증가가 전 세계 항경련제 시장을 견인할 것으로 예상됩니다. 예를 들어, 2016년 1월, 마이란 N.V.는 400 mg 및 600 mg 용량의 페르바메이트 정 USP를 출시했습니다. 펠바메이트 정은 간질 치료에 사용되는 펠바톨 정제의 제네릭 의약품입니다. 이 약물은 간질을 앓고 있는 성인의 이차성 전신 발작을 동반하거나 동반하지 않는 부분 발작의 치료, 그리고 소아의 레녹스-가스토 증후군에 수반되는 부분 발작 및 전신 발작의 치료에 권장됩니다.
그러나 항경련제의 잠재적인 부작용으로 인해, 예측 기간 동안 전 세계 항경련제 시장의 성장이 저해될 것으로 예상됩니다. 예를 들어, 'Journal of Family Practice'에 따르면, 항경련제의 부작용으로서 간질 환자 치료에 사용되는 페니토인은 '태아 히단토인 증후군(FHS)'이라고 통칭되는 일련의 기형을 유발한다는 점이 꼽힙니다. 이 증후군은 말단 지골의 형성 부전이나 골화, 그리고 두개안면 기형이 다양한 정도로 나타나는 것이 특징입니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하고 있는 경쟁 전략에 관한 중요한 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 매개변수를 바탕으로 전 세계 항경련제 시장의 주요 기업 개요을 작성하고 있습니다. 구체적으로는 기업 개요, 재무 실적, 제품 포트폴리오, 사업 전개 지역, 유통 전략, 주요 발전 사항 및 전략입니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 정부 정책, 기술 업그레이드, 시장 확대 및 마케팅 전략과 관련하여 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 본 '세계 항경련제 시장 보고서'는 투자자, 제품 제조업체, 의약품 시장 유통업체 및 공급업체, 조사·컨설팅 회사, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 항경련제 시장 : 세대별, 2021-2033년
제5장 세계의 항경련제 시장 : 투여 경로별, 2021-2033년
제6장 세계의 항경련제 시장 : 유통 채널별, 2021-2033년
제7장 세계의 항경련제 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSM 26.07.08Antiepileptic Drugs Market is estimated to be valued at USD 7.74 Bn in 2026 and is expected to reach USD 9.85 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 7.74 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.50% | 2033 Value Projection: | USD 9.85 Bn |
Epilepsy is a chronic disorder that affects the brain and causes frequent seizures. Seizures are bursts of electrical activity in the brain that temporarily affects its functioning. Epilepsy can start at any age, but usually starts either in childhood or in people over the age of 60. There are several tests conducted to determine the activity in the brain. An electroencephalogram (EEG) is conducted on epilepsy patients to check for unusual electrical activities in the brain. A brain scan is also used to spot problems in the brain that is sometimes caused due to epilepsy such as an unusual growth (brain tumour), damage to the brain, and scarring in the brain. Magnetic resonance imaging (MRI) scan is also used to conduct the brain scan in patients suffering from epilepsy. It uses magnetic fields and radio waves to create an image of the brain. Anti-epileptic drugs are also used in the treatment of epilepsy, which are categorized into three generations.
Market Dynamics
Increasing number of product launches is expected to drive the global anti-epileptic drug market. For instance, in January 2016, Mylan N.V. launched Felbamate tablets USP in 400 mg and 600 mg dosages. Felbamate tablets are the generic version of Felbatol tablets used for the treatment of epilepsy. These are recommended for the treatment of partial seizures, with or without secondary generalizations in adults with epilepsy and in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.
However, growth of the global anti-epileptic drug market is expected to be hampered over the forecast period, owing to potential side effects of the anti-epileptic drugs. For instance, according to the Journal of Family Practice, the side effects of anti-epileptic drugs include, the medication Phenytoin, which is used for treating epilepsy patients causes a pattern of defects collectively called the Fetal Hydantoin Syndrome (FHS), which is characterized by variable degrees of hypoplasia and ossification of the distal phalanges and craniofacial abnormalities.
Key features of the study:
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
- It profiles key players in the global anti-epileptic drug market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study are Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy's Laboratories Ltd., Alkem Labs, SK Biopharmaceuticals, Eisai Co., Ltd., Angelini S.p.a., Sun Pharmaceutical Industries Ltd., UCB S.A, Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., Bausch Health Companies Inc.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics.
- The global anti-epileptic drug market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for drug market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
- Global Anti-epileptic Drugs Market, By Generation (Revenue, USD Bn, 2021 - 2033)
- First Generation
- Second Generation
- Third Generation
- Global Anti-epileptic Drugs Market, By Route of Administration (Revenue, USD Bn, 2021 - 2033)
- Oral
- Intravenous
- Global Anti-epileptic Drugs Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Anti-epileptic Drugs Market, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- By Country:
- U.S.
- Canada
- By Generation:
- First Generation
- Second Generation
- Third Generation
- By Route of Administration:
- Oral
- Intravenous
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Generation:
- First Generation
- Second Generation
- Third Generation
- By Route of Administration:
- Oral
- Intravenous
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Generation:
- First Generation
- Second Generation
- Third Generation
- By Route of Administration:
- Oral
- Intravenous
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Generation:
- First Generation
- Second Generation
- Third Generation
- By Route of Administration:
- Oral
- Intravenous
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Generation:
- First Generation
- Second Generation
- Third Generation
- By Route of Administration:
- Oral
- Intravenous
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Generation:
- First Generation
- Second Generation
- Third Generation
- By Route of Administration:
- Oral
- Intravenous
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- Company Profiles
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GlaxoSmithKline Plc.
- Johnson & Johnson Service, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Zogenix
- Dr. Reddy's Laboratories Ltd.
- Alkem Labs
- SK Biopharmaceuticals
- Eisai Co., Ltd.
- Angelini S.p.a
- Sun Pharmaceutical Industries Ltd.
- UCB S.A
- Sanofi S.A.
- Sumitomo Dainippon Pharma Co., Ltd.
- Bausch Health Companies Inc.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Generation
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Key Developments
- Mergers, Acquisitions and Collaborations
- Recent Trends
- Recent Launches/Approvals
- Regulatory Scenario
- Reimbursement Scenario
- PEST Analysis
- Porter's Analysis
4. Global Antiepileptic Drugs Market, By Generation, 2021-2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- First Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
- Second Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Third Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
5. Global Antiepileptic Drugs Market, By Route of Administration, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
6. Global Antiepileptic Drugs Market, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- E-commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
7. Global Antiepileptic Drugs Market, By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- North America
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth ,By Country, 2021 -2033, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and , Y-o-Y Growth, By Country/Region, 2021 -2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- GlaxoSmithKline Plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Johnson & Johnson Service, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Zogenix
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Shanghai Zhimeng Biopharma, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Alkem Labs
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- SK Biopharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Eisai Co, Ltd
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- IAMA Therapeutics
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Angelini S.p.a
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- UCB S.A
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Marinus Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sumitomo Dainippon Pharma Co., Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bausch Health Companies Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Analysts' Views
- Novartis AG
9. Section
- References
- Research Methodology
- About us and Sales Contact
